Axa S.A. Kymera Therapeutics, Inc. Transaction History

Axa S.A.

$29.5 Billion
Q1 2025

A detailed history of Axa S.A. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 108,994 shares of KYMR stock, worth $4.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

108,994

Previous 109,136 0.13%

Holding current value

$4.43 Million

Previous $4.39 Million 32.05%

% of portfolio

0.01%

Previous 0.01%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$27.37 - $44.36 $3,886 - $6,299	-142 Reduced 0.13%	108,994 $2.98 Million
Q4 2024 Feb 14, 2025	SELL	$39.06 - $51.84 $6,874 - $9,123	-176 Reduced 0.16%	109,136 $4.39 Million
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $995 - $1,729	33 Added 0.03%	109,312 $5.17 Million
Q2 2024 Feb 25, 2025	BUY	$29.85 - $39.42 $4,268 - $5,637	143 Added 0.13%	109,279 $3.26 Million
Q2 2024 Aug 14, 2024	BUY	$29.85 - $39.42 $1,850 - $2,444	62 Added 0.06%	109,279 $3.26 Million
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $2.5 Million - $4.76 Million	109,217 New	109,217 $4.39 Million

Others Institutions Holding KYMR

# of Institutions

185

Shares Held

67.9M

Call Options Held

223K

Put Options Held

241K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.22B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account